ahlam1399
06-16-2015, 01:53 AM
Avalanche eye gene therapy meets safety goal
June 15 (Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/47435c7a/sc/32/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/1/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/1/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/2/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/2/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/3/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/3/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2.htm)
http://adchoice.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/ach.img (http://adchoice.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/ach.htm)http://pi.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2t.imghttp://pi2.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=_HVuh6fBU7Y:bNVd3PRrOSY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=_HVuh6fBU7Y:bNVd3PRrOSY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/_HVuh6fBU7Y
June 15 (Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/47435c7a/sc/32/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/1/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/1/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/2/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/2/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/3/rc.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/rc/3/rc.htm)
http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2.img (http://da.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2.htm)
http://adchoice.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/ach.img (http://adchoice.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/ach.htm)http://pi.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2t.imghttp://pi2.feedsportal.com/r/231064379699/u/49/f/654213/c/35217/s/47435c7a/sc/32/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=_HVuh6fBU7Y:bNVd3PRrOSY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=_HVuh6fBU7Y:bNVd3PRrOSY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=_HVuh6fBU7Y:bNVd3PRrOSY:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/_HVuh6fBU7Y